How to buy ZIOPHARM Oncology stock (ZIOP)

ZIOPHARM Oncology is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a trailing 12-month revenue of around $398,000.

Our top picks for where to buy ZIOPHARM Oncology stock

Buy ZIOPHARM Oncology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ZIOPHARM Oncology stock price (NASDAQ: ZIOP)

Use our graph to track the performance of ZIOP stocks over time.

ZIOPHARM Oncology shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$1.07
200-day moving average more info button	$1.89
Wall St. target price	$3.92
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.42

Is it a good time to buy ZIOPHARM Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ZIOPHARM Oncology financials

Revenue TTM	$398,000
Gross profit TTM	$-52,696,000
Return on assets TTM	-39.32%
Return on equity TTM	-84.01%
Profit margin	0%
Book value	$0.32
Market Capitalization more info button	$187.1 million

TTM: trailing 12 months

ZIOPHARM Oncology share dividends

We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.

Have ZIOPHARM Oncology's shares ever split?

ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.

ZIOPHARM Oncology share price volatility

Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 1.6868. This would suggest that ZIOPHARM Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ZIOPHARM Oncology overview

ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.

Frequently asked questions

What percentage of ZIOPHARM Oncology is owned by insiders or institutions?
Currently 9.927% of ZIOPHARM Oncology shares are held by insiders and 56.28% by institutions. How many people work for ZIOPHARM Oncology?
Latest data suggests 103 work at ZIOPHARM Oncology. When does the fiscal year end for ZIOPHARM Oncology?
ZIOPHARM Oncology's fiscal year ends in December. Where is ZIOPHARM Oncology based?
ZIOPHARM Oncology's address is: Parris Building 34, Boston, MA, United States, 02129 What is ZIOPHARM Oncology's ISIN number?
ZIOPHARM Oncology's international securities identification number is: US98973P1012 What is ZIOPHARM Oncology's CUSIP number?
ZIOPHARM Oncology's Committee on Uniform Securities Identification Procedures number is: 98973P101